Nano‐gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer

Abstract

The aim of this study was to provide a new effective carrier for rescuing the sensitivity of drug‐resistant in breast cancer cells. Nano‐gold micelles loaded with Dox and Elacridar (FP‐ssD@A‐E) were chemically synthesised. With the increase in the amount of Dox and Elacridar, the encapsulation rate of FP‐ssD@A‐E gradually increased, and the drug loading rate gradually decreased. FP‐ss@A‐E had a sustained‐release effect. Dox, Elacridar, FP‐ss@AuNPs, and FP‐ssD@A‐E significantly improved cell apoptosis, in which, FP‐ssD@A‐E was the most significant. FP‐ssD@A‐E significantly decreased the cell viability and improved the Dox uptake. The levels of VEGFR‐1, P‐gp, IL‐6, and i‐NOS were significantly decreased after Dox, Dox + Elacridar, FP‐ss@AuNPs, and FP‐ssD@A‐E treatment. It was worth noting that FP‐ssD@A‐E had the most significant effects. The prepared FP‐ssD@A‐E micelles, which were spherical in shape, uniform in particle size distribution, and had good drug loading performance and encapsulation efficiency.

Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives

“…Bioinspired nanomedicines mimic the properties of endogenous molecules that traverse the BBB, such as specific peptides or transport proteins, to facilitate brain-targeted drug delivery. Additionally, engineered nanocarriers can exploit receptor-mediated transcytosis or bypass mechanisms to penetrate the BBB while maintaining therapeutic efficacy and minimizing neurotoxicity [ 296 ]. Tumor Microenvironment Permeation: The complex tumor microenvironment poses significant challenges for drug delivery, including heterogeneous blood vessel distribution, elevated interstitial fluid pressure, and dense extracellular matrix components.…”

“…Bioinspired nanomedicines mimic the properties of endogenous molecules that traverse the BBB, such as specific peptides or transport proteins, to facilitate brain-targeted drug delivery. Additionally, engineered nanocarriers can exploit receptor-mediated transcytosis or bypass mechanisms to penetrate the BBB while maintaining therapeutic efficacy and minimizing neurotoxicity [ 296 ].…”